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Working Together in a Challenging Environment

Working Together in a Challenging Environment:
The Jefferson Industry Advisory Council (JIAC)
__________________________________________
Under the leadership of Dr. Geno Merli, the Ludwig Kind Professor of
Medicine and former Senior Associate Dean for CME, Dr. Richard Wender,
the Alumni Professor and Chairman of the Department of Family Medicine
and Chairman of the Jefferson Medical College CME Committee, and Dr.
David Nash, the Dr. Raymond C. and Doris N. Grandon Professor of Health
Policy and Chairman of the Department of Health Policy, the Jefferson
Industry Advisory Council (JIAC) serves as a forum in which representatives
from across the Thomas Jefferson University can meet with representatives
from pharmaceutical, biotechnical and other sectors of the healthcare
industry to explore opportunities for partnering more effectively in
recognition of current environmental constraints.

A capacity crowd filled DiPalma auditorium for a special session of the Jefferson
Industry Advisory Council, presented jointly by the Department of Health Policy and
the Office of Continuing Medical Education on November 22, 2004. The topic,
“Working Together in a Challenging Environment,” represented the continuation of
an ongoing conversation about defining and negotiating relationships between
academia and the pharmaceutical industry – an issue recognized as one of the most
pressing in health care today.
The first of two invited speakers was Dr. Arnold S. Relman whom Dr. Nash
introduced as a true “Renaissance man” in the medical arena with impressive
credentials as a physician, teacher, and researcher, former editor of the New England
Journal of Medicine, and thought leader at the national level. Dr. Relman provoked
and challenged the audience with his views on the separation of pharmaceutical
marketing from medical education. He began by drawing distinctions between
medicine and the pharmaceutical industry in terms of focus (“a serving profession
without fiduciary responsibility versus a product-centered industry with primary
responsibility to investors”) and educational approach (educating its own using
evidence-based knowledge that is independent of the Market versus marketing and
informing”). Noting the public’s reliance on medical education that is focused on the
best and safest way to diagnose and treat a condition without regard for
marketability, he contended that collaboration between academic educators and the
pharmaceutical industry represents “an inherent conflict of interest.” In the area of
research, Dr. Relman spoke in favor of collaboration on well-regulated activities. He
appraised the American College of Graduate Medical Education (ACGME) guidelines
as inadequate because they are not enforceable. Rather than each medical institution
developing its own guidelines, he advised that the American Association of Medical
Colleges (AAMC) be persuaded to convene a public meeting of the major medical
schools to develop set of policies all can subscribe to.
Citing statistics generated by the Securities and Exchange Commission (SEC), Dr.
Relman reasoned that the huge amounts spent by pharmaceutical companies on
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continuing medical education (CME) inevitably and unavoidably influence topics and
content. “This sets a bad precedent for fledgling physicians, undermines professional
self-respect, weakens public trust in the profession, and increases drug
costs – employers and patients are paying for it in the final analysis.”
Currently, 60-70 percent of the cost of CME is borne by the pharmaceutical industry.
What do we do without industry support? Dr. Relman’s proposed solution included
more modest meetings (“The biggest names are not necessarily the best teachers.”),
greater use of full-time faculty by providers, more efficient pedagogic methods, and
increases in student tuition.
The second speaker, James G. Sheehan JD (Associate U.S. Attorney and Chief of the
Civil Division, US Department of Justice), spoke on “Current Enforcement Issues in
Health Care Fraud”. Among the three general areas (research fraud, corporate
governance/quality and errors, and “dead patients”), he noted that most collusion is
found in financial coding and payment. Citing historical examples, he pointed
out that research fraud is neither a recent phenomenon nor is it motivated by pure
greed. Falsification, overstatement or misreporting data, and misrepresenting
credentials are the most common events.
How does the financial conflict-of-interest component of research affect the
credibility of the science? Some studies suggest that 40 percent of researchers are
aware of financial misconduct but have not reported it, in large part because of a
belief that the ends (i.e., getting funding for the next important grant) justifies the
means (i.e., misreporting). He stressed the importance of effective organizational
compliance plans to minimize the risk of fraud.
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